Cystic Fibrosis Foundation Invests an Additional $5 Million in BiomX
March 19, 2024
March 19, 2024
BETHESDA, Maryland, March 19 -- Cystic Fibrosis Foundation issued the following news release on March 18, 2024:
The Cystic Fibrosis Foundation announced today that it has invested an additional $5 million in BiomX Inc. to support a Phase 2b clinical trial to test the efficacy of bacteriophage (phage) therapy in treating chronic Pseudomonas aeruginosa infections -- the second most common type of lung infection in people living with cystic fibrosis.
Previously, the Founda . . .
The Cystic Fibrosis Foundation announced today that it has invested an additional $5 million in BiomX Inc. to support a Phase 2b clinical trial to test the efficacy of bacteriophage (phage) therapy in treating chronic Pseudomonas aeruginosa infections -- the second most common type of lung infection in people living with cystic fibrosis.
Previously, the Founda . . .